Intercept Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-11.25	-16.79	-1.08	-0.67
Depreciation & Amortization	0.18	0	0	0
Asset Writedown & Restructuring Costs	0	0	-	-
Stock-Based Compensation	6.4	13.57	-	-
Other Operating Activities	0.02	-	-	-
Change in Inventory	-	-	0.16	-0.16
Change in Other Net Operating Assets	3.79	0.24	0.1	0.11
Operating Cash Flow	-0.87	-2.98	-0.81	-0.72
Capital Expenditures	-	-0.01	-0	-
Other Investing Activities	-2.05	-	-	-
Investing Cash Flow	-2.05	-0.01	-0	-
Short-Term Debt Issued	-	-	-	0.69
Long-Term Debt Issued	3.48	3.39	0.87	-
Total Debt Issued	3.48	3.39	0.87	0.69
Long-Term Debt Repaid	-0.17	-	-	-
Net Debt Issued (Repaid)	3.31	3.39	0.87	0.69
Other Financing Activities	-0.01	0	-	-
Financing Cash Flow	3.3	3.39	0.87	0.69
Foreign Exchange Rate Adjustments	0.03	-0.46	-0.01	0.01
Net Cash Flow	0.42	-0.06	0.05	-0.03
Free Cash Flow	-0.87	-2.99	-0.81	-0.72
Free Cash Flow Per Share	-0.01	-0.02	-0.01	-
Cash Interest Paid	0.01	-	-	-
Levered Free Cash Flow	4.74	3.28	-0.53	-
Unlevered Free Cash Flow	4.75	3.28	-0.53	-
Change in Net Working Capital	-3.22	-0.24	-0.15	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.